Objectives: Postoperative atrial fibrillation (POAF) has been associated with an inflammatory response to the surgical procedure. n-3 long-chain polyunsaturated fatty acids (LC-PUFA) have been proposed for the prevention of POAF. We investigated the relationship between the plasma concentration of inflammatory mediators, levels of n-3 LC-PUFA in red blood cell (RBC) membrane lipids, and the risk of POAF after coronary artery bypass grafting (CABG). Methods: A total of 125 patients who underwent CABG were studied. Inflammatory mediators in plasma and the content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in RBC membranes were assessed. Results: Sixty-two patients (49.6%) developed POAF. The POAF group had higher RBC levels of total n-3 LC-PUFA and DHA than did patients remaining in sinus rhythm (p < 0.05). Of the inflammatory mediators, only postoperative interleukin-6 levels differed, being higher in the POAF group (p < 0.05). Inflammatory mediators were not independent predictors of POAF by multivariable logistic regression analysis. Higher levels of DHA and total n-3 LC-PUFA in RBC membranes, measured immediately prior to CABG and on postoperative day 3, were linearly associated with an increased risk of POAF (p < 0.05). Conclusions: Our findings suggest that inflammatory mediators are not associated with the occurrence of POAF. Interestingly, high n-3 LC-PUFA levels in RBC membranes appear to increase the risk of POAF.

Keywords:
Atrial fibrillation, Postoperative, n-3 polyunsaturated fatty acids, Inflammation

1.
Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ, Cohn LH, Burstin HR: Predictors of atrial fibrillation after coronary artery surgery. Circulation 1996;94:390-397.
2.
Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT: A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-1729.
3.
Laffey JG, Boylan JF, Cheng DC: The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-252.
4.
Anselmi A, Possati G, Gaudino M: Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg 2009;88:326-333.
5.
Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G, Norkunas G, Kalinauskas G, Sirvydis V, Aidietis A, Lip GY: Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010;104:122-127.
6.
Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack C: Activation of the complement system during and after cardiopulmonary bypass surgery: post surgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-3548.
7.
Maisel WH, Rawn JD, Stevenson WG: Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-1073.
8.
Skuladottir GV, Heidarsdottir R, Arnar DO, Torfason B, Edvardsson V, Gottskalksson G, Palsson R, Indridason O: Plasma n-3 and n-6 fatty acids and the incidence of atrial fibrillation following coronary artery bypass graft surgery. Eur J Clin Invest 2011;41:995-1003.
9.
Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-1519S.
10.
Ariel A, Serhan CN: Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007;28:176-183.
11.
Chapkin RS, Kim W, Lupton JR, McMurray DN: Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 2009;8:187-191.
12.
Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646-2652.
13.
Li G-R, Sun HY, Zhang ZH, Cheng LC, Chiu SW, Tse HF, Lau CP: Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res 2009;81:286-293.
14.
Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB: Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology. Heart Rhythm 2011;8:562-568.
15.
Savelieva I, Camm AJ: Polyunsaturated fatty acids for prevention of atrial fibrillation: a ‘fishy' story. Europace 2011;13:149-152.
16.
Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M: N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-1728.
17.
Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR, Erdogan A: Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 2009;57:276-280.
18.
Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC: Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010;3:46-53.
19.
Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G, Palsson R, Indridason OS: Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356-363.
20.
Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, Sullivan TR, James MJ, Young GD: Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol 2011;108:851-856.
21.
Nattel S, Van Wagoner D: Atrial fibrillation: therapy with omega-3 fatty acids - is the case closed? Nat Rev Cardiol 2011;8:126-128.
22.
Metcalf RG, Cleland LG, Gibson RA, Roberts-Thomson KC, Edwards JR, Sanders P, Stuklis R, James MJ, Young GD: Relation between blood and atrial fatty acids in patients undergoing cardiac bypass surgery. Am J Clin Nutr 2010;91:528-534.
23.
Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M: Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997;38:2012-2022.
24.
Skogstrand K, Thorsen P, Norgaard-Pedersen B, Schendel DE, Sorensen LC, Hougaard DM: Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 2005;51:1854-1866.
25.
Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917.
26.
Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR, Siscovick DS, Mozaffarian D: Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation 2012;125:1084-1093.
27.
Liu T, Korantzopoulos P, Shehata M, Li G, Wang X, Kaul S: Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart 2011;97:1034-1040.
28.
Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP: Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009;120:2315-2321.
29.
Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner T, Latini R, Libby P, Lombardi F, O'Gara P, Page R, Tavazzi L, Tognoni G, OPERA Investigators: Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012;308:2001-2011.
30.
Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC, GESICA Investigators: Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol 2013;61:463-468.
31.
Sands SA, Reid KJ, Windsor SL, Harris WS: The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 2005;40:343-347.
32.
Camm AJ, Savelieva I: Fish oil for secondary prevention of atrial fibrillation: should we still believe in its anti-arrhythmic effect? Circulation 2011;124:1093-1096.
33.
Den Ruitjer HM, Berecki G, Opthof T, Verkerk AO, Zock PL, Coronel R: Pro- and antiarrhythmic properties of a diet rich in fish oils. Cardiovasc Res 2007;73:316-325.
34.
Wilhelm M, Tobias R, Asskali F, Kraechner R, Kuly S, Klinghammer L, Boehles H, Daniel WG: Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am Heart J 2008;155:971-977.
35.
Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T: Atrial fibrillation following cardiac surgery: risk analysis and long term survival. J Cardiothorac Surg 2012;7:87-93.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.